Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.70 |
| ▸ | MMP2 | P08253 | 2/20 | 0.66 |
| ▸ | MMP3 | P08254 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MAOB | P27338 | 3/20 | 0.65 |
| ▸ | FLT3 | P36888 | 3/20 | 0.65 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Genkwanin SCHEMBL5469869 | 0.93 | CYP19A1 (0.74) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Naringenin SCHEMBL28072458 | 0.93 | BACE1 (0.70) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Naringenin SCHEMBL6073059 | 0.93 | BACE1 (0.70) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Naringenin SCHEMBL28072460 | 0.93 | BACE1 (0.70) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Homoeriodictyol SCHEMBL17651827 | 0.90 | MMP9 (0.72) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Isosakutanetin SCHEMBL676015 | 0.84 | CYP1A1 (1.00) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Isosakutanetin SCHEMBL29358328 | 0.84 | CYP1A1 (1.00) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Isosakutanetin SCHEMBL31128790 | 0.84 | CYP1A1 (1.00) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Isosakutanetin SCHEMBL5067423 | 0.84 | CYP1A1 (1.00) | MMP9CYP1A1CYP1A2CYP1B1MMP2 | |
| Acacetin SCHEMBL107712 | 0.81 | CYP1B1 (1.00) | CYP1A1CYP1A2CYP1B1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329575-B2 | Regulatory sequence for plants | CERES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180223303-A1 | SEQUENCE-DETERMINED DNA FRAGMENTS AND CORRESPONDING POLYPEPTIDES ENCODED THEREBY | CERES INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160076046-A1 | PROMOTER, PROMOTER CONTROL ELEMENTS, AND COMBINATIONS, AND USES THEREOF | CERES, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9029523-B2 | Promoter, promoter control elements, and combinations, and uses thereof | CERES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150033417-A9 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI (US) | 2015-01-29 | — | — | US | disclosed |
| US-8877916-B2 | Promoter, promoter control elements, and combinations, and uses thereof | CERES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120159672-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | ALEXANDROV NICKOLAI | 2011-08-04 | — | — | US | disclosed |
| US-20090265815-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded therapy | ALEXANDROV NICKOLAI | 2009-10-22 | — | — | US | disclosed |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | CERES, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20060150283-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | ALEXANDROV NICKOLAI | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037426-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | MMP9 3348/4885CYP1A1 4779/4885CYP1A2 4859/4885 |
| US-20150033417-A9 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | MMP9 1808/4885CYP1A1 4560/4885CYP1A2 4747/4885 |
| US-20120084885-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | MMP9 1796/4885CYP1A1 4569/4885CYP1A2 4749/4885 |
| US-20070214517-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | MMP9 3348/4885CYP1A1 4779/4885CYP1A2 4859/4885 |
| US-20110191912-A1 | Promoter, promoter control elements, and combinations, and uses thereof | RNGTT, GTF3C5, GTF3C1 | MMP9 1808/4885CYP1A1 4560/4885CYP1A2 4747/4885 |
| US-20120159672-A1 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | RNGTT, CPSF1, CPSF6 | MMP9 3348/4885CYP1A1 4779/4885CYP1A2 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.